10x Genomics (TXG) Receives a Buy from Morgan Stanley
Morgan Stanley analyst Tejas Savant maintained a Buy rating on 10x Genomics (TXG – Research Report) today and set a price target of $26.00. The ...
10x Genomics price target lowered to $15 from $18 at Barclays
Barclays lowered the firm’s price target on 10x Genomics (TXG) to $15 from $18 and keeps an Overweight rating on the shares.Maximize Your ...
Life Science Company 10x Genomics Struggles With Profitability, Analyst Says 2025 Guidance Bakes In NIH Funding Uncertainties
Genomics reported a Q4 EPS loss of $(0.40), missing estimates, while revenue declined 10% year over year. Analysts lowered price targets amid profitability concerns.
10x Genomics Shares Tumble on Fear Over Cuts to NIH
A Wednesday night earnings report left big questions about how the spending reductions would affect the company.
10x Genomics, Inc. (NASDAQ:TXG) Q4 2024 Earnings Call Transcript
Q4 2024 Earnings Call Transcript February 12, 2025 10x Genomics, Inc. misses on earnings expectations. Reported EPS is $-0.4 ...
10X Genomics股价跌至52周新低11.89美元
生物科技行业面临挑战，10X Genomics Inc (TXG)股价跌至52周新低，触及11.89美元。根据 InvestingPro 数据显示，技术指标表明该股票已处于超卖区域，公司保持着4.9的健康流动比率。这一最新价格水平凸显了公司股价的急剧下跌，过去一年累计下跌75.65%。投资者正在应对行业整体压力和公司特定不利因素的双重影响，导致持续抛售，最终使公司股价创下新低。这个52周低点清晰地 ...
实验室设备股因NIH削减预算而下跌
Investing.com -- 实验室工具设备行业的公司股票，包括Bruker、Illumina、Quanterix、Bio-Techne、10X Genomics和Qiagen，在盘前交易中出现下跌。这一下跌趋势是在美国国立卫生研究院（NIH）宣布计划通过降低研究机构向政府收取的最高间接成本率来大幅减少对医学研究人员的报销后出现的。